Anti-inflammatory potential of Empagliflozin.

Keywords: Empagliflozin; SGLT2 inhibition; Anti-inflammatory potential; Nephroprotection; Human proximal tubulus EN Empagliflozin SGLT2 inhibition Anti-inflammatory potential Nephroprotection Human proximal tubulus 573 576 4 03/29/21 20210401 NES 210401 Dear Editor A recent article by Maayah and coworkers elegantly described a survival benefit with the use of the SGLT2 inhibitor Empagliflozin (Empa) in a murine model of LPS-induced septic shock (Maayah et al. [20]). Based on the aforementioned central role of systemic and renal tissue inflammation during development and progression of CKD, it is tempting to speculate that anti-inflammatory effects of SGLT2i at least partially contribute to the nephroprotective effect observed in large clinical trials among diabetic and non-diabetic patients. The positive risk/benefit ratio found for SGLT2i use among non-diabetic CKD and heart failure patients in the DAPA-CKD (Heerspink et al. [14]) and DAPA-HF (McMurray et al. [21]) trials, respectively, might allow to test SGLT2i in the management of other non-diabetic kidney diseases. 1:CAS:528:DC%2BC1cXhtVyjtLY%3D. 10.1681/ASN.2016020177 2 Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. [Extracted from the article]